Fused Bicyclic Compounds, Compositions And Applications Thereof

Impetis Biosciences Limited.
Granted App No 201741008624 Patent 398154 Chemical

Patent information

IP India · live record
Application number
201741008624
Filing date
13 March 2017
Status
Granted
Legal status
Inforce
Publication number
37/2018
Publication type
INA
Invention field
Chemical
Patent number
398154
Grant date
31 May 2022
Next renewal due
13 March 2027

Abstract

The present invention relates to fused bicyclic compounds that are inhibitors of GPR91, their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions containing them. These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of GPR91. The disclosure also relates to the process of preparation of the fused bicyclic compounds of Formula (I), and to pharmaceutical compositions containing them.

Applicants

1
India
IMPETIS BIOSCIENCES LIMITED. Bombay House, 1 st Floor, Homi Mody Street, Mumbai City, Maharashtra, 400001, India.

Inventors

10
India
SHAIKH, NADIMADVINUS THERAPEUTICS LIMITED(A TATA ENTERPRISE) QUANTUM TOWER, PLAT NO.9, RAJIV GANDHI INFOTECH PARK, PHASE -1, HINJEWADI, PUNE 411057, MAHARASHTRA, INDIA.
India
THAKKAR, MAHESHADVINUS THERAPEUTICS LIMITED(A TATA ENTERPRISE) QUANTUM TOWER, PLAT NO.9, RAJIV GANDHI INFOTECH PARK, PHASE -1, HINJEWADI, PUNE 411057, MAHARASHTRA, INDIA.
India
SHINDE,SHAILESHADVINUS THERAPEUTICS LIMITED(A TATA ENTERPRISE) QUANTUM TOWER, PLAT NO.9, RAJIV GANDHI INFOTECH PARK, PHASE -1, HINJEWADI, PUNE 411057, MAHARASHTRA, INDIA.
India
JOSHI ,MANOJADVINUS THERAPEUTICS LIMITED(A TATA ENTERPRISE) QUANTUM TOWER, PLAT NO.9, RAJIV GANDHI INFOTECH PARK, PHASE -1, HINJEWADI, PUNE 411057, MAHARASHTRA, INDIA.
India
NAIK, KESHAVADVINUS THERAPEUTICS LIMITED(A TATA ENTERPRISE) QUANTUM TOWER, PLAT NO.9, RAJIV GANDHI INFOTECH PARK, PHASE -1, HINJEWADI, PUNE 411057, MAHARASHTRA, INDIA.
India
BHALERAO, AMITADVINUS THERAPEUTICS LIMITED(A TATA ENTERPRISE) QUANTUM TOWER, PLAT NO.9, RAJIV GANDHI INFOTECH PARK, PHASE -1, HINJEWADI, PUNE 411057, MAHARASHTRA, INDIA.
India
MUKIM ,MAYURADVINUS THERAPEUTICS LIMITED(A TATA ENTERPRISE) QUANTUM TOWER, PLAT NO.9, RAJIV GANDHI INFOTECH PARK, PHASE -1, HINJEWADI, PUNE 411057, MAHARASHTRA, INDIA.
India
BHUNIYA ,DEBNATHADVINUS THERAPEUTICS LIMITED(A TATA ENTERPRISE) QUANTUM TOWER, PLAT NO.9, RAJIV GANDHI INFOTECH PARK, PHASE -1, HINJEWADI, PUNE 411057, MAHARASHTRA, INDIA.
India
KULKARNI ,BHEEMASHANKARADVINUS THERAPEUTICS LIMITED(A TATA ENTERPRISE) QUANTUM TOWER, PLAT NO.9, RAJIV GANDHI INFOTECH PARK, PHASE -1, HINJEWADI, PUNE 411057, MAHARASHTRA, INDIA.
India
MOOKHTIAR, KASIMADVINUS THERAPEUTICS LIMITED(A TATA ENTERPRISE) QUANTUM TOWER, PLAT NO.9, RAJIV GANDHI INFOTECH PARK, PHASE -1, HINJEWADI, PUNE 411057, MAHARASHTRA, INDIA.

Specification

Show full textCollapse

1. A compounds of Formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts thereof, wherein A is substituted or unsubstituted 5-10 membered bicyclic or polycyclic fully or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from O, N, or S; D is selected from CR1 or N; G is selected from –C(O)OR1, –C(O)NRaRb, -SOpR1, -NR1SO2R1 or 5-7 membered monocyclic fully or partially unsaturated heterocyclic ring having 1-4 heteroatoms independently selected from O, N or S; R1 is selected from hydrogen, C1-6 haloalkyl, C1-6 alkyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl or C5-10 heterocyclyl, wherein C6-10 aryl, C3-6 cycloalkyl, C5-10 heteroaryl, and C5-10 heterocyclyl are optionally substituted with C1-6 alkyl; R2, R3, and R4 are independently selected from hydrogen, C1-6 alkyl, C3-6 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C(O)R1, R1C(O)NRaRb, -OC(O)R1, R6, -(CRaRb)mC(O)R6, - (CRaRb)mNR7R8, -NRaC(O)-, -C1-6 alkoxy C(O)NRaRb, -SO2NRaRb-, -NRaC(O)NRaRb, C1-6 alkoxyamino, azido, cyano, halogen, hydroxy, C1-6 alkylhydroxy, C1-6 haloalkyl, perhalo C1-6 alkyl, -C(S)Ra, –C(O)OR1, C1-6 alkyl C(O)ORb, OC(O) C1-6 alkyloxy, ORaC(O)ORb- C1-6 alkylOC(O) O C1-6 alkyloxy, -SO3H, -S(O)pR6, -S(O)2NR7R8 C1-6 alkylthio or nitro; R6 is selected from the group consisting of hydrogen, -(CRaRb)mOR6, halogen, C1-6 haloalkyl, -(CRaRb)mC(O)R6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6

cycloalkyl, or C5-10 heterocyclyl, wherein C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, C5-10 heterocyclyl are optionally substituted with C1-6 alkyl, wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and C5-10 heterocyclyl are optionally substituted with one or more substituents selected from hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, halogen, C1-6 haloalkyl, perhalo-C1-6 alkyl, cyano, -cyano C1-6 alkyl-, amino, –C(O)OR1, OR5, -OC(O)R6, -(CRaRb)mC(O)NR7R8, - NR6C(O)R6, -SR6, -S(O)pR6, -S(O)2NR7R8 or -NR6S(O)2R6; R5, R7, and R8 are independently selected from the group consisting of hydrogen, - (CRaRb)mOR6, C1-6 haloalkyl, -(CRaRb)mC(O)R6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, C5-10 heterocyclyl, wherein , C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and C5-10 heterocyclyl are optionally substituted with C1-6 alkyl, or R7, and R8 can be taken together to form a monocyclic or a bicyclic saturated or partially unsaturated carbocyclyl or heterocyclyl ring optionally having 1-5 heteroatoms selected from O, N, or S, wherein the monocyclic or a bicyclic saturated or partially unsaturated carbocyclyl or heterocyclyl ring is further optionally substituted with 1 to 4 substituents independently selected from halogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, nitro, cyano, - (CRaRb)mOR6, -SR6, -(CRaRb)mNR7R8, oxo, C1-6 alkylsulfonyl, -(CRaRb)mCOOR6, - (CRaRb)mC(O)NR7R8, C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, or C5-10 heteroaryl,wherein C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, and C5-10 heteroaryl are optionally substituted with C1-6 alkyl; Ra, and Rb are independently selected from the group consisting of hydrogen, -OR6, halogen, C1-6 haloalkyl, perhalo C1-6 alkyl, -SOpR1, and C1-6 alkyl; or Ra, and Rb can be taken together to form a monocyclic or a bicyclic saturated or partially unsaturated carbocyclyl or heterocyclyl ring optionally having 1-5 heteroatoms selected from O, N, or S; m is 0 to 4; n is 0 to 3; p is 0-2. 2. The compounds of Formula (I) their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts thereof, as claimed in claim 1, wherein A is substituted or unsubstituted 5-10 membered bicyclic or polycyclic fully or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from O, N, or S; D is selected from CR1, or N;

G is selected from –C(O)OR1, –C(O)NRaRb, -NR1SO2R1 or 5 membered monocyclic fully or partially unsaturated heterocyclic ring having 1-4 heteroatoms independently selected from O, N, or S; R1 is selected from hydrogen, C1-6 haloalkyl, C1-6 alkyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, or C5-10 heterocyclyl, wherein C6-10 aryl, C3-6 cycloalkyl, C5-10 heteroaryl, and C5-10 heterocyclyl are optionally substituted with C1-6 alkyl; R2, R3, and R4 are independently selected from hydrogen, C1-6 alkyl, C3-6 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C(O)R1, R1C(O)NRaRb, -OC(O)R1, R6, -(CRaRb)mC(O)R6, -(CRaRb)mNR7R8, -NRaC(O)-, -C1-6 alkoxy C(O)NRaRb, -SO2NRaRb-, -NRaC(O)NRaRb, NRaOH, C1-6 alkoxyamino, azido, cyano, halogen, hydroxy, C1-6 alkylhydroxy, C1-6 haloalkyl, perhalo C1-6 alkyl, -C(S)Ra, C(O)OR1, C1-6 alkyl C(O)ORb, OC(O) C1-6 alkyloxy, ORaC(O)ORb- C1-6 alkylOC(O) O C1-6 alkyloxy, -SO3H, -S(O)pR6, -S(O)2NR7R8 C1-6 alkylthio or nitro; R6 is selected from the group consisting of hydrogen, -(CRaRb)mOR6, halogen, C1-6 haloalkyl, -(CRaRb)mC(O)R6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, or C5-10 heterocyclyl, wherein C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, C5-10 heterocyclyl are optionally substituted with C1-6 alkyl, wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and C5-10 heterocyclyl are optionally substituted with one or more substituents selected from hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, halogen, C1-6 haloalkyl, perhalo-C1-6 alkyl, cyano, -cyano C1-6 alkyl-, amino, –C(O)OR1, OR5, -OC(O)R6, -(CRaRb)mC(O)NR7R8, -NR6C(O)R6, -SR6, -S(O)pR6, -S(O)2NR7R8, or -NR6S(O)2R6; R5, R7, and R8 are independently selected from the group consisting of hydrogen, -(CRaRb)mOR6, C1-6 haloalkyl, -(CRaRb)mC(O)R6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, C5-10 heterocyclyl, wherein , C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and C5-10 heterocyclyl are optionally substituted with C1-6 alkyl or R5, R7 and R8 can be taken together to form a monocyclic or a bicyclic saturated or partially unsaturated carbocyclyl or heterocyclyl ring optionally having 1-5 heteroatoms selected from O, N, S, wherein the monocyclic or a bicyclic ring carbocyclyl or heterocyclyl is further optionally substituted with 1 to 4 substituents independently selected from halogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, nitro, cyano, -(CRaRb)mOR6, -SR6, -(CRaRb)mNR7R8, oxo, C1-6 alkylsulfonyl, -(CRaRb)mCOOR6, -(CRaRb)mC(O)NR7R8, C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, or C5-10 heteroaryl, wherein C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, and C5-10 heteroaryl are optionally substituted with C1-6 alkyl;

Ra, and Rb are independently selected from the group consisting of hydrogen, -OR6, halogen, C1-6 haloalkyl, perhalo C1-6 alkyl, -SOpR1, and C1-6 alkyl; or Ra, and Rb can be taken together to form a monocyclic or a bicyclic ring saturated or partially unsaturated optionally having 1-5 heteroatoms selected from O, N or S; m is 0 to 4; n is 1 to 3; p is 0-2. 3. The compounds of Formula (I) their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts thereof, as claimed in claim 1, wherein A is substituted or unsubstituted 5-10 membered bicyclic or polycyclic fully or partially unsaturated heterocyclic ring having 1-5 heteroatom independently selected from O, N, or S; D is selected from CR1, or N; G is selected from –C(O)OR1, –C(O)NRaRb, -NR1SO2R1, or 5 membered monocyclic fully or partially unsaturated heterocyclic ring having 1-4 heteroatoms independently selected from O, N or S; R1 is selected from hydrogen, C1-6 haloalkyl, C1-6 alkyl, C5-10 heteroaryl, or C3-6 cycloalkyl, wherein C3-6 cycloalkyl, and C5-10 heteroaryl are optionally substituted with C1-6 alkyl; R2, R3, and R4 are independently selected from hydrogen, C1-6 alkyl, C3-6 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C(O)R1, R1C(O)NRaRb, -OC(O)R1, R6, -(CRaRb)mC(O)R6, - (CRaRb)mNR7R8, -NRaC(O)-, -C1-6 alkoxy C(O)NRaRb, -SO2NRaRb-, -NRaC(O)NRaRb, NRaOH, C1-6 alkoxyamino, azido, cyano, halogen, hydroxy, C1-6 alkyl hydroxy, C1-6 haloalkyl, perhalo C1-6 alkyl, -C(S)Ra, C(O)OR1, C1-6 alkyl C(O)ORb, OC(O) C1-6 alkyloxy, ORaC(O)ORb- C1-6 alkylOC(O) O C1-6 alkyloxy, -SO3H, -S(O)pR6, -S(O)2NR7R8 C1-6 alkylthio or nitro; R6 is selected from the group consisting of hydrogen, -(CRaRb)mOR6, halogen, C1-6 haloalkyl, -(CRaRb)mC(O)R6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, or C5-10 heterocyclyl, wherein C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, C5-10 heterocyclyl are optionally substituted with C1-6 alkyl; wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and C5-10 heterocyclyl are optionally substituted with one or more substituents selected from hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, halogen, C1-6 haloalkyl, perhalo-C1-6 alkyl, cyano, -cyano C1-6 alkyl-, amino, –C(O)OR1, OR5, -OC(O)R6, -(CRaRb)mC(O)NR7R8, - NR6C(O)R6, -SR6, -S(O)pR6, -S(O)2NR7R8, or -NR6S(O)2R6;

R5, R7, and R8 are independently selected from the group consisting of hydrogen, -(CRaRb)mOR6, C1-6 haloalkyl, -(CRaRb)mC(O)R6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, C5-10 heterocyclyl, wherein , C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and C5-10 heterocyclyl are optionally substituted with C1-6 alkyl or R7 and R8 can be taken together to form a monocyclic or a bicyclic saturated or partially unsaturated carbocyclyl or heterocyclyl ring optionally having 1-5 heteroatoms selected from O, N or S, wherein the monocyclic or a bicyclic ring carbocyclyl or heterocyclyl is further optionally substituted with 1 to 4 substituents independently selected from halogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, nitro, cyano, -(CRaRb)mOR6, -SR6, -(CRaRb)mNR7R8, oxo, C1-6 alkylsulfonyl, -(CRaRb)mCOOR6, -(CRaRb)mC(O)NR7R8, C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, or C5-10 heteroaryl,wherein C3-6 cycloalkyl, C6-10 aryl, C5-10, and C5-10 heteroaryl are optionally substituted with C1-6 alkyl; Ra, and Rb are independently selected from the group consisting of hydrogen, -OR6, halogen, C1-6 haloalkyl, perhalo C1-6 alkyl, -SOpR1, and C1-6 alkyl or Ra, and Rb can be taken together to form a monocyclic or a bicyclic ring saturated or partially unsaturated optionally having 1-5 heteroatoms selected from O, N or S; m is 0 to 4; n is 1 to 3; p is 0-2. 4. The compounds of Formula (I) their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts thereof, as claimed in claim 1, wherein A is substituted or unsubstituted 5-10 membered bicyclic or polycyclic unsaturated or partially unsaturated heterocyclic ring having 1-5 heteroatom independently selected from O, N or S; D is selected from CR1 or N; G is selected from –C(O)OR1, –C(O)NRaRb, -NR1SO2R1 or 5 membered monocyclic fully or partially unsaturated heterocyclic ring having 1-4 heteroatoms independently selected from O, N, or S; R1 is selected from hydrogen, C1-6 haloalkyl, C1-6 alkyl, C5-10 heteroaryl, or C3-6 cycloalkyl, wherein C3-6 cycloalkyl, and C5-10 heteroaryl are optionally substituted with C1-6 alkyl; R2, R3, and R4 are independently selected from hydrogen, C1-6 alkyl, C3-6 cycloalkyl, C1-6 alkoxy, C(O)R1, R1C(O)NRaRb, -OC(O)R1, R6, -(CRaRb)mC(O)R6, -(CRaRb)mNR7R8, - NRaC(O)-, -C1-6 alkoxy C(O)NRaRb, -NRaC(O)NRaRb, NRaOH, C1-6 alkoxyamino, azido,

cyano, halogen, hydroxy, C1-6 alkyl hydroxy, C1-6 haloalkyl, perhalo C1-6 alkyl, C(O)OR1, C1-6 alkyl C(O)ORb, OC(O) C1-6 alkyloxy, ORaC(O)ORb- C1-6 alkylOC(O) O C1-6 alkyloxy, or nitro; R6 is selected from the group consisting of hydrogen, -(CRaRb)mOR6, halogen, C1-6 haloalkyl, -(CRaRb)mC(O)R6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, or C5-10 heterocyclyl, wherein C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, C5-10 heterocyclyl are optionally substituted with C1-6 alkyl; wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and heterocyclyl are optionally substituted with one or more substituents selected from hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, halogen, C1-6 haloalkyl, perhalo-C1-6 alkyl, cyano, -cyano C1-6 alkyl-, amino, –C(O)OR1, OR5, -OC(O)R6, -(CRaRb)mC(O)NR7R8, -NR6C(O)R6, -SR6, -S(O)pR6, -S(O)2NR7R8, or -NR6S(O)2R6; R5, R7, and R8 are independently selected from the group consisting of hydrogen, -(CRaRb)mOR6, C1-6 haloalkyl, -(CRaRb)mC(O)R6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, C5-10 heterocyclyl, wherein , C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and C5-10 heterocyclyl are optionally substituted with C1-6 alkyl or R7 and R8 can be taken together to form a monocyclic or a bicyclic saturated or partially unsaturated carbocyclyl or heterocyclyl ring optionally having 1-5 heteroatoms selected from O, N or S, wherein the monocyclic or a bicyclic ring carbocyclyl or heterocyclyl is further optionally substituted with 1 to 4 substituents independently selected from halogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, nitro, cyano, -(CRaRb)mOR6, -SR6, -(CRaRb)mNR7R8, oxo, C1-6 alkylsulfonyl, -(CRaRb)mCOOR6, -(CRaRb)mC(O)NR7R8, C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, or C5-10 heteroaryl,wherein C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, and C5-10 heteroaryl are optionally substituted with C1-6 alkyl; Ra, and Rb are independently selected from the group consisting of hydrogen, -OR6, halogen, C1-6 haloalkyl, perhalo C1-6 alkyl, -SOpR1, and C1-6 alkyl or Ra, and Rb can be taken together to form a monocyclic or a bicyclic ring saturated or partially unsaturated optionally having 1-5 heteroatoms selected from O, N or S; m is 0 to 4; n is 1 to 3; p is 0-2. 5. The compounds of Formula (I) their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts thereof, as claimed in claim 1, wherein

A is substituted or unsubstituted 5-10 membered bicyclic or polycyclic unsaturated or partially unsaturated heterocyclic ring having 1-5 heteroatom independently selected from O, N or S; D is selected from CR1 or N; G is selected from –C(O)OR1, –C(O)NRaRb, -NR1SO2R1 or 5 membered monocyclic fully unsaturated or partially unsaturated heterocyclic ring having 1-4 heteroatom independently selected from O, N, or S; R1 is selected from hydrogen, C1-6 haloalkyl, C1-6 alkyl, C5-10 heteroaryl, or C3-6 cycloalkyl, wherein C3-6 cycloalkyl, and C5-10 heteroaryl are optionally substituted with C1-6 alkyl; R2, R3, and R4 are independently selected from hydrogen, C1-6 alkyl, C3-6 cycloalkyl, C1-6 alkoxy, C(O)R1, R1C(O)NH2, -OC(O)R1, C(O)OR1, R6, -(CRaRb)mC(O)R6, -(CRaRb)mNR7R8, -NRaC(O)-, -C1-6 alkoxy C(O)NRaRb, -NRaC(O)NRaRb, NRaOH, C1-6 alkoxyamino, azido, cyano, halogen, hydroxy, C1-6 alkyl hydroxy, C1-6 haloalkyl, perhalo C1-6 alkyl, C1-6 alkyl C(O)ORb, OC(O) C1-6 alkyloxy, ORaC(O)ORb- C1-6 alkylOC(O) O C1-6 alkyloxy, or nitro; R6 is selected from the group consisting of hydrogen, -(CRaRb)mOR6, halogen, C1-6 haloalkyl, -(CRaRb)mC(O)R6, C1-6 alkyl, C5-10 heteroaryl, C3-6 cycloalkyl, or C5-10 heterocyclyl, wherein C5-10 heteroaryl, C3-6 cycloalkyl, C5-10 heterocyclyl are optionally substituted with C1-6 alkyl; wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and C5-10 heterocyclyl are optionally substituted with one or more substituents selected from hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, halogen, C1-6 haloalkyl, perhalo-C1-6 alkyl, cyano, -cyano C1-6 alkyl-, amino, –C(O)OR1, OR5, -OC(O)R6, -(CRaRb)mC(O)NR7R8, -NR6C(O)R6, -SR6, -S(O)pR6, -S(O)2NR7R8 or -NR6S(O)2R6; R5, R7, and R8 are independently selected from the group consisting of hydrogen, -(CRaRb)mOR6, C1-6 haloalkyl, -(CRaRb)mC(O)R6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, C5-10 heterocyclyl, wherein , C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and C5-10 heterocyclyl are optionally substituted with C1-6 alkyl or R7 and R8 can be taken together to form a monocyclic or a bicyclic saturated or partially unsaturated carbocyclyl or heterocyclyl ring optionally having 1-5 heteroatoms selected from O, N, or S, wherein the monocyclic or a bicyclic ring carbocyclyl or heterocyclyl is further optionally substituted with 1 to 4 substituents independently selected from halogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, nitro, cyano, -(CRaRb)mOR6, -SR6, -(CRaRb)mNR7R8, oxo, C1-6 alkylsulfonyl, -(CRaRb)mCOOR6, -(CRaRb)mC(O)NR7R8, C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, or C5-10 heteroaryl,wherein C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, and C5-10 heteroaryl are optionally substituted with C1-6 alkyl;

Ra, and Rb are independently selected from the group consisting of hydrogen, -OR6, halogen, C1-6 haloalkyl, perhalo C1-6 alkyl, -SOpR1, and C1-6 alkyl or Ra, and Rb can be taken together to form a monocyclic or a bicyclic ring saturated or partially unsaturated optionally having 1-5 heteroatoms selected from O, N, or S; m is 0 to 4; n is 1 to 3; p is 0-2. 6. The compounds of Formula (I) their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts thereof, as claimed in claim 1, wherein A is substituted or unsubstituted 5-10 membered bicyclic or polycyclic unsaturated or partially unsaturated heterocyclic ring having 1-5 heteroatom independently selected from O, N or S; D is selected from CR1 or N; G is selected from –C(O)OR1, –C(O)NRaRb, -NR1SO2R1 or 5 membered monocyclic fully unsaturated or partially unsaturated heterocyclic ring having 1-4 heteroatom independently selected from O, N, or S; R1 is selected from hydrogen, C1-6 haloalkyl, C1-6 alkyl, C5-10 heteroaryl, or C3-6 cycloalkyl, wherein C3-6 cycloalkyl, and C5-10 heteroaryl are optionally substituted with C1-6 alkyl; R2, R3, and R4 are independently selected from hydrogen, C1-6 alkyl, C3-6 cycloalkyl, C1-6 alkoxy, C(O)R1, R1C(O)NH2, -OC(O)R1, R6, C(O)OR1, -(CRaRb)mC(O)R6, -(CRaRb)mNR7R8, -NRaC(O)-, -C1-6 alkoxy C(O)NRaRb, -NRaC(O)NRaRb, NRaOH, C1-6 alkoxyamino, azido, cyano, halogen, hydroxy, C1-6 alkyl hydroxy, C1-6 haloalkyl, perhalo C1-6 alkyl, C1-6 alkyl C(O)ORb, OC(O) C1-6 alkyloxy, ORaC(O)ORb- C1-6 alkylOC(O) O C1-6 alkyloxy, or nitro; R6 is selected from the group consisting of hydrogen, -(CRaRb)mOR6, halogen, C1-6 haloalkyl, -(CRaRb)mC(O)R6, C1-6 alkyl, C5-10 heteroaryl, C3-6 cycloalkyl, or C5-10 heterocyclyl, wherein C5-10 heteroaryl, C3-6 cycloalkyl, C5-10 heterocyclyl are optionally substituted with C1-6 alkyl; wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and C5-10 heterocyclyl are optionally substituted with one or more substituents selected from hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, halogen, C1-6 haloalkyl, perhalo-C1-6 alkyl, cyano, -cyano C1-6 alkyl-, amino, –C(O)OR1, OR5, -OC(O)R6, -(CRaRb)mC(O)NR7R8, - NR6C(O)R6, -SR6, -S(O)pR6, -S(O)2NR7R8, or -NR6S(O)2R6; R5, R7, and R8 are independently selected from the group consisting of hydrogen, - (CRaRb)mOR6, C1-4 haloalkyl, -(CRaRb)mC(O)R6, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C6-8

aryl, 5-7 membered heteroaryl, C3-5 cycloalkyl, 5-7 membered heterocyclyl, wherein , C6-8 aryl, 5-7 membered heteroaryl, C3-5 cycloalkyl, and 5-7 membered heterocyclyl are optionally substituted with C1-6 alkyl or R7 and R8 can be taken together to form a monocyclic or a bicyclic saturated or partially unsaturated carbocyclyl or heterocyclyl ring optionally having 1-5 heteroatoms selected from O, N, or S, wherein the monocyclic or a bicyclic ring carbocyclyl or heterocyclyl is further optionally substituted with 1 to 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, nitro, cyano, -(CRaRb)mOR6, -SR6, -(CRaRb)mNR7R8, oxo, C1-6 alkylsulfonyl, -(CRaRb)mCOOR6, -(CRaRb)mC(O)NR7R8, C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, or C5-10 heteroaryl,wherein C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, and C5-10 heteroaryl are optionally substituted with C1-6 alkyl; Ra, and Rb are independently selected from the group consisting of hydrogen, -OR6, halogen, C1-6 haloalkyl, perhalo C1-6 alkyl, -SOpR1, and C1-6 alkyl or Ra, and Rb can be taken together to form a monocyclic or a bicyclic ring saturated or partially unsaturated optionally having 1-5 heteroatoms selected from O, N or S; m is 0 to 4; n is 1 to 3; p is 0-2. 7. The compounds of Formula (I) their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts thereof, as claimed in claim 1, wherein A is substituted or unsubstituted C5-10 bicyclic or polycyclic unsaturated or partially unsaturated heterocyclic ring having 1-5 heteroatom independently selected from O, N or S; D is selected from CR1 or N; G is selected from –C(O)OR1, –C(O)NRaRb, -NR1SO2R1 or 5 membered monocyclic fully unsaturated or partially unsaturated heterocyclic ring having 1-4 heteroatom independently selected from O, N, or S; R1 is selected from hydrogen, C1-6 haloalkyl, C1-6 alkyl, C5-10 heteroaryl, or C3-6 cycloalkyl, wherein C3-6 cycloalkyl, and C5-10 heteroaryl are optionally substituted with C1-6 alkyl; R2, R3, and R4 are independently selected from hydrogen, C1-6 alkyl, C3-6 cycloalkyl, C1-6 alkoxy, C(O)R1, R1C(O)NH2, -OC(O)R1, R6, C(O)OR1, -(CRaRb)mC(O)R6, -(CRaRb)mNR7R8, -NRaC(O)-, -C1-6 alkoxy C(O)NRaRb, -NRaC(O)NRaRb, NRaOH, C1-6 alkoxyamino, azido, cyano, halogen, hydroxy, C1-6 alkyl hydroxy, C1-6 haloalkyl, perhalo C1-6 alkyl, C1-6 alkyl C(O)ORb, OC(O) C1-6 alkyloxy, ORaC(O)ORb- C1-6 alkylOC(O) O C1-6 alkyloxy, or nitro;

R6 is selected from the group consisting of hydrogen, -(CRaRb)mOR6, halogen, C1-6 haloalkyl, -(CRaRb)mC(O)R6, C1-6 alkyl, C5-10 heteroaryl, C3-6 cycloalkyl, or C5-10 heterocyclyl, wherein C5-10 heteroaryl, C3-6 cycloalkyl, C5-10 heterocyclyl are optionally substituted with C1-6 alkyl; wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and C5-10 heterocyclyl are optionally substituted with one or more substituents selected from hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, halogen, C1-6 haloalkyl, perhalo-C1-6 alkyl, cyano, -cyano C1-6 alkyl-, amino, –C(O)OR1, OR5, -OC(O)R6, -(CRaRb)mC(O)NR7R8, - NR6C(O)R6, -SR6, -S(O)pR6, -S(O)2NR7R8 or -NR6S(O)2R6; R5, R7, and R8 are independently selected from the group consisting of hydrogen, - (CRaRb)mOR6, C1-4 haloalkyl, -(CRaRb)mC(O)R6, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C6-8 aryl, 5-7 membered heteroaryl, C3-5 cycloalkyl, 5-7 membered heterocyclyl, wherein , C6-8 aryl, 5-7 membered heteroaryl, C3-5 cycloalkyl, and 5-7 membered heterocyclyl are optionally substituted with C1-6 alkyl; or R7 and R8 can be taken together to form a monocyclic or a bicyclic saturated or partially unsaturated carbocyclyl or heterocyclyl ring optionally having 1-4 heteroatoms selected from O, N, or S, wherein the monocyclic or a bicyclic ring carbocyclyl or heterocyclyl is further optionally substituted with 1 to 4 substituents independently selected from halo, C1-6 alkyl, cyano, -(CRaRb)mOR6, -SR6, oxo, -(CRaRb)mCOOR6, C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, or C5-10 heteroaryl, wherein C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, and C5-10 heteroaryl are optionally substituted with C1-6 alkyl; Ra, and Rb are independently selected from the group consisting of hydrogen, -OR6, halogen, C1-6 haloalkyl, perhalo C1-6 alkyl, -SOpR1, and C1-6 alkyl; or Ra, and Rb can be taken together to form a monocyclic or a bicyclic ring saturated or partially unsaturated optionally having 1-5 heteroatoms selected from O, N, or S; m is 0 to 4; n is 1 to 3; p is 0-2. 8. The compounds of Formula (I) their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts thereof, as claimed in claim 1, wherein A is substituted or unsubstituted 5-10 membered bicyclic or polycyclic unsaturated or partially unsaturated heterocyclic ring having 1-5 heteroatom independently selected from O, N, or S; D is selected from CR1 or N;

G is selected from –C(O)OR1, –C(O)NRaRb, -NR1SO2R1 or 5 membered monocyclic fully unsaturated or partially unsaturated heterocyclic ring having 1-4 heteroatom independently selected from O, N, or S; R1 is selected from hydrogen, C1-6 haloalkyl, C1-6 alkyl, C5-10 heteroaryl, or C3-6 cycloalkyl, wherein C3-6 cycloalkyl, and C5-10 heteroaryl are optionally substituted with C1-6 alkyl; R2, R3, and R4 are independently selected from hydrogen, C1-6 alkyl, C3-6 cycloalkyl, C1-6 alkoxy, C(O)R1, R1C(O)NH2, -OC(O)R1, R6, C(O)OR1, -(CRaRb)mC(O)R6, -(CRaRb)mNR7R8, -NRaC(O)-, -C1-6 alkoxy C(O)NRaRb, -NRaC(O)NRaRb, NRaOH, C1-6 alkoxyamino, azido, cyano, halogen, hydroxy, C1-6 alkyl hydroxy, C1-6 haloalkyl, perhalo C1-6 alkyl, C1-6 alkyl C(O)ORb, OC(O) C1-6 alkyloxy, ORaC(O)ORb- C1-6 alkylOC(O) O C1-6 alkyloxy, or nitro; R6 is selected from the group consisting of hydrogen, -(CRaRb)mOR6, halogen, C1-6 haloalkyl, -(CRaRb)mC(O)R6, C1-6 alkyl, C5-10 heteroaryl, C3-6 cycloalkyl, or C5-10 heterocyclyl, wherein C5-10 heteroaryl, C3-6 cycloalkyl, C5-10 heterocyclyl are optionally substituted with C1-6 alkyl; wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and C5-10 heterocyclyl are optionally substituted with one or more substituents selected from hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, halogen, C1-6 haloalkyl, perhalo-C1-6 alkyl, cyano, -cyano C1-6 alkyl-, amino, –C(O)OR1, OR5, -OC(O)R6, -(CRaRb)mC(O)NR7R8, - NR6C(O)R6, -SR6, -S(O)pR6, -S(O)2NR7R8, or -NR6S(O)2R6; R5, R7, and R8 are independently selected from the group consisting of hydrogen, - (CRaRb)mOR6, C1-4 haloalkyl, -(CRaRb)mC(O)R6, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C6-8 aryl, 5-7 membered heteroaryl, C3-5 cycloalkyl, 5-7 membered heterocyclyl, wherein , C6-8 aryl, 5-7 membered heteroaryl, C3-5 cycloalkyl, and 5-7 membered heterocyclyl are optionally substituted with C1-6 alkyl; or R7 and R8 can be taken together to form a monocyclic or a bicyclic saturated or partially unsaturated carbocyclyl or heterocyclyl ring optionally having 1-4 heteroatoms selected from O, N, or S, wherein the monocyclic or a bicyclic ring carbocyclyl or heterocyclyl is further optionally substituted with 1 to 4 substituents independently selected from halo, C1-6 alkyl, cyano, -(CRaRb)mOR6, -SR6, oxo, -(CRaRb)mCOOR6, C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, or C5-10 heteroaryl, wherein C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, and C5-10 heteroaryl are optionally substituted with C1-6 alkyl; Ra, and Rb are independently selected from the group consisting of hydrogen, -OR6, halogen, C1-6 haloalkyl, perhalo C1-6 alkyl, -SOpR1, and C1-6 alkyl; or m is 0 to 3; n is 1 to 3;

9. The compound of Formula (I) as claimed in any one of the claims 1-8, tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts thereof, which is selected from a group consisting of: 2-[3-[4-(8-isoquinolyloxy)-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A1), 2-[3-[4-phthalazin-5-yloxy-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A2), 3-[3-[4-phthalazin-5-yloxy-2-(trifluoromethyl)phenoxy]phenyl]propanoic acid (A3), 2-[3-[4-(8-chlorophthalazin-5-yl)oxy-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A4), 2-[3-[4-(1-methylindazol-7-yl)oxy-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A5), 2-[3-[4-(6-quinolyloxy)-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A6), 3-[3-[4-imidazo[1,2-a]pyridin-8-yloxy-2-(trifluoromethyl)phenoxy]phenyl]propanoic acid (A7), 2-[3-[4-[(5-fluoro-8-isoquinolyl)oxy]-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A8), 2-[3-[4-quinazolin-5-yloxy-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A9), 3-[3-[4-[(2-methyl-3,4-dihydro-1H-isoquinolin-8-yl)oxy]-2-(trifluoromethyl) phenoxy] phenyl]propanoic acid (A10), 3-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yloxy)-2-(trifluoromethyl)phenoxy]phenyl]propanoic acid (A11), 3-[3-[4-(8-quinolyloxy)-2-(trifluoromethyl)phenoxy]phenyl]propanoic acid (A12), 3-[3-[4-(4-quinolyloxy)-2-(trifluoromethyl)phenoxy]phenyl]propanoic acid (A13), 3-[3-[4-(5-isoquinolyloxy)-2-(trifluoromethyl)phenoxy]phenyl]propanoic acid (A14), 2-[3-[4-(2-methylindazol-4-yl)oxy-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A15), 2-[3-[4-(1-methylindazol-4-yl)oxy-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A16), 2-[3-[4-([1,2,4]triazolo[4,3-a]pyridin-5-yloxy)-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A17), 2-[3-[4-(3,4-dihydro-2H-1,4-benzoxazin-6-yloxy)-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A18), 2-[3-[4-([1,2,4]triazolo[4,3-a]pyridin-7-yloxy)-2-(trifluoromethyl)phenoxy] phenyl]acetic acid (A19), 2-[3-[4-[1-(oxetan-3-yl)indol-6-yl]oxy-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A20), 2-[3-[4-[1-(oxetan-3-yl)indazol-6-yl]oxy-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A21),

2-[3-[4-[2-(oxetan-3-yl)indazol-6-yl]oxy-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A22), 2-[3-[4-[1-(oxetan-3-yl)indazol-5-yl]oxy-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A23), 2-[3-[4-[2-(oxetan-3-yl)indazol-5-yl]oxy-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A24), 2-[3-[4-[3-(oxetan-3-yl)benzotriazol-5-yl]oxy-2-(trifluoromethyl) phenoxy]phenyl]acetic acid (A25), 2-[3-[4-[3-(oxetan-3-yl)benzimidazol-5-yl]oxy-2-(trifluoromethyl)phenoxy] phenyl]acetic acid (A26), 2-[3-[4-[2-methyl-3-(oxetan-3-yl)benzimidazol-5-yl]oxy-2-(trifluoromethyl) phenoxy] phenyl]acetic acid (A27), 2-[3-[2-(difluoromethyl)-4-[2-methyl-3-(oxetan-3-yl)benzimidazol-5-yl]oxy-phenoxy] phenyl]acetic acid (A28), 2-[3-[4-[1-(oxetan-3-yl)imidazo[4,5-b]pyridin-6-yl]oxy-2-(trifluoromethyl) phenoxy] phenyl]acetic acid (A29), 2-[3-[4-[1-(oxetan-3-yl)pyrrolo[2,3-b]pyridin-6-yl]oxy-2-(trifluoromethyl) phenoxy] phenyl]acetic acid (A30), 6-[4-[3-(carboxymethyl)phenoxy]-3-(trifluoromethyl)phenoxy]imidazo[1,5-a]pyridine-3-carboxylic acid (A31), 2-[3-[4-[1-(carboxymethyl)indol-5-yl]oxy-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A32), 2-[3-[4-[1-(carboxymethyl)indol-6-yl]oxy-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A33), 3-[4-[4-(8-isoquinolyloxy)-2-(trifluoromethyl)phenoxy]phenyl]propanoic acid (A34), 3-[3-[4-(2-methylindazol-5-yl)oxy-2-(trifluoromethyl)phenoxy]phenyl]propanoic acid (A35), 2-[3-[[5-(8-isoquinolyloxy)-3-(trifluoromethyl)-2-pyridyl]oxy]phenyl]acetic acid (A36), 3-[3-[4-imidazo[1,2-a]pyridin-5-yloxy-2-(trifluoromethyl)phenoxy]phenyl]propanoic acid (A37), 2-[3-[2-cyclopropyl-4-(8-isoquinolyloxy)phenoxy]phenyl]acetic acid (A38), 2-[3-[2-cyclopropyl-4-[2-methyl-3-(oxetan-3-yl)benzimidazol-5-yl]oxy-phenoxy] phenyl]acetic acid (A39), 2-[3-[4-[(1-chloro-8-isoquinolyl)oxy]-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A40), 2-[3-[4-[(1-methyl-8-isoquinolyl)oxy]-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A41),

3-[3-[4-(8-isoquinolyloxy)-2-(trifluoromethyl)phenoxy]phenyl]propanoic acid (A42), 3-[3-[4-(1,2,3,4-tetrahydroisoquinolin-8-yloxy)-2-(trifluoromethyl) phenoxy] phenyl] propanoic acid (A43), 3-[3-[4-indan-1-yloxy-2-(trifluoromethyl)phenoxy]phenyl]propanoic acid (A44), 3-[3-[4-(1H-indazol-5-yloxy)-2-(trifluoromethyl)phenoxy]phenyl]propanoic acid (A45), 2-[3-[4-[(3-cyano-1H-indazol-5-yl)oxy]-2-(trifluoromethyl) phenoxy]phenyl]acetic acid (A46), 5-[4-[3-(carboxymethyl)phenoxy]-3-(trifluoromethyl)phenoxy]-1H-indazole-3-carboxylic acid (A47), 2-[3-[4-(1H-indazol-4-yloxy)-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (A48), 2-[3-[4-imidazo[1,5-a]pyridin-5-yloxy-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (B1), 2-[3-[4-imidazo[1,5-a]pyridin-8-yloxy-2-(trifluoromethyl) phenoxy]phenyl]acetic acid (B2), 2-[3-[4-(3-methylimidazo[1,5-a]pyridin-5-yl)oxy-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (B3), 2-[3-[4-(3-methylimidazo[1,5-a]pyridin-8-yl)oxy-2-(trifluoromethyl)phenoxy]phenyl]acetic acid (B4), 2-[3-[4-[3-(oxetan-3-yl)imidazo[1,5-a]pyridin-6-yl]oxy-2-(trifluoromethyl) phenoxy] phenyl] acetic acid (B5), 2-[3-[4-(8-isoquinolyloxy)-2-(trifluoromethyl)phenoxy]phenyl]-N-methylsulfonyl-acetamide (C1), 3-[3-[4-(8-isoquinolyloxy)-2-(trifluoromethyl)phenoxy]phenyl]propanamide (C2), 2-[3-[4-(8-isoquinolyloxy)-2-(trifluoromethyl)phenoxy]phenyl]acetamide (C3), 8-[4-[3-[2-(4H-1,2,4-triazol-3-yl)ethyl]phenoxy]-3-(trifluoromethyl)phenoxy]isoquinoline (D1), 8-[4-[3-[2-(1H-tetrazol-5-yl)ethyl]phenoxy]-3-(trifluoromethyl)phenoxy]isoquinoline (D2), 8-[4-[3-(1H-tetrazol-5-ylmethyl)phenoxy]-3-(trifluoromethyl) phenoxy]isoquinoline (D3), and 2-[3-[4-(8-isoquinolyloxy)-3-(trifluoromethyl)phenoxy]phenyl]acetic acid (E1). 10. A process of preparation of compounds of Formula (I) as claimed in any of claims 1 to 9 or its tautomers, polymorphs, stereoisomers, prodrugs, solvate, co-crystals or pharmaceutically acceptable salts thereof. 11. The process as claimed in claimed in claim 10, wherein the compounds of Formula I are obtained by reacting compounds of Formula II, and compounds of Formula III.

12. The process as claimed in claimed in claim 11, wherein the G of Formula II is selected from –C(O)OR1, –C(O)NRaRb, -NR1SO2R1 or 5-7 membered monocyclic fully or partially unsaturated heterocyclic ring having 1-4 heteroatom independently selected from O, N, or S; R1 is selected from hydrogen, C1-6 haloalkyl, C1-6 alkyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, or C5-10 heterocyclyl, wherein C6-10 aryl, C3-6 cycloalkyl, C5-10 heteroaryl, and C5-10 heterocyclyl are optionally substituted with C1-6 alkyl; R2, and R3 are independently selected from hydrogen, C1-6 alkyl, C3-6 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C(O)R1, R1C(O)NH2, -OC(O)R1, R6, C(O)OR1, -(CRaRb)mC(O)R6, -(CRaRb)mNR7R8, -NRaC(O)-, -C1-6 alkoxy C(O)NRaRb, -SO2NRaRb-, -NRaC(O)NRaRb, NRaOH, C1-6 alkoxyamino, azido, cyano, halogen, hydroxy, C1-6 alkyl hydroxy, C1-6 haloalkyl, perhalo C1-6 alkyl, -C(S)Ra, C1-6 alkyl C(O)ORb, OC(O) C1-6 alkyloxy, ORaC(O)ORb- C1-6 alkylOC(O) O C1-6 alkyloxy, -SO3H, -S(O)pR6, -S(O)2NR7R8 C1-6 alkylthio, or nitro; R6 is selected from the group consisting of hydrogen, -(CRaRb)mOR6, halogen, C1-6 haloalkyl, -(CRaRb)mC(O)R6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, or C5-10 heterocyclyl, wherein C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, C5-10 heterocyclyl are optionally substituted with C1-6 alkyl; wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and C5-10 heterocyclyl are optionally substituted with one or more substituents selected from hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, halogen, C1-6 haloalkyl, perhalo-C1-6 alkyl, cyano, -cyano C1-6 alkyl-, amino, –C(O)OR1, OR5, -OC(O)R6, -(CRaRb)mC(O)NR7R8, -NR6C(O)R6, -SR6, -S(O)pR6, -S(O)2NR7R8, or -NR6S(O)2R6; R5, R7, and R8 are independently selected from the group consisting of hydrogen, -(CRaRb)mOR6, C1-6 haloalkyl, -(CRaRb)mC(O)R6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, C5-10 heterocyclyl, wherein , C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and C5-10 heterocyclyl are optionally substituted with C1-6 alkyl; or

R7 and R8 can be taken together to form a monocyclic or a bicyclic saturated or partially unsaturated carbocyclyl or heterocyclyl ring optionally having 1-5 heteroatoms selected from O, N, or S, wherein the monocyclic or a bicyclic ring carbocyclyl or heterocyclyl is further optionally substituted with 1 to 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, nitro, cyano, -(CRaRb)mOR6, -SR6, -(CRaRb)mNR7R8, oxo, C1-6 alkylsulfonyl, -(CRaRb)mCOOR6, -(CRaRb)mC(O)NR7R8, C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, or C5-10 heteroaryl,wherein C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, and C5-10 heteroaryl are optionally substituted with C1-6 alkyl; Ra, and Rb are independently selected from the group consisting of hydrogen, -OR6, halogen, C1-6 haloalkyl, perhalo C1-6 alkyl, -SOpR1, and C1-6 alkyl; or Ra, and Rb can be taken together to form a monocyclic or a bicyclic ring saturated or partially unsaturated optionally having 1-5 heteroatoms selected from O, N, or S; m is 0 to 4; n is 0 to 3; p is 0-2; and A of Formula III is substituted or unsubstituted 5-10 membered bicyclic or polycyclic fully or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from O, N or S; R4 of Formula III is independently selected from hydrogen, C1-6 alkyl, C3-6 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C(O)R1, R1C(O)NH2, -OC(O)R1, R6, -(CRaRb)mC(O)R6, -(CRaRb)mNR7R8, -NRaC(O)-, -C1-6 alkoxy C(O)NRaRb, -SO2NRaRb-, -NRaC(O)NRaRb, NRaOH, C1-6 alkoxyamino, azido, cyano, halogen, hydroxy, C1-6 alkyl hydroxy, C1-6 haloalkyl, perhalo C1-6 alkyl, -C(S)Ra, , C1-6 alkyl C(O)ORb, OC(O) C1-6 alkyloxy, ORaC(O)ORb- C1-6 alkylOC(O) O C1-6 alkyloxy, -SO3H, -S(O)pR6, -S(O)2NR7R8 C1-6 alkylthio, or nitro; R6 is selected from the group consisting of hydrogen, -(CRaRb)mOR6, halogen, C1-6 haloalkyl, -(CRaRb)mC(O)R6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, or C5-10 heterocyclyl, wherein C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, C5-10 heterocyclyl are optionally substituted with C1-6 alkyl, wherein C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and C5-10 heterocyclyl are optionally substituted with one or more substituents selected from hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxyalkyl, halogen, C1-6 haloalkyl, perhalo-C1-6 alkyl, cyano, -cyano C1-6 alkyl-, amino, –C(O)OR1, OR5, -OC(O)R6, -(CRaRb)mC(O)NR7R8, -NR6C(O)R6, -SR6, -S(O)pR6, -S(O)2NR7R8, or -NR6S(O)2R6; R5, R7, and R8 are independently selected from the group consisting of hydrogen, -(CRaRb)mOR6, C1-6 haloalkyl, -(CRaRb)mC(O)R6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, C5-10 heterocyclyl, wherein , C6-10 aryl, C5-10 heteroaryl, C3-6 cycloalkyl, and C5-10 heterocyclyl are optionally substituted with C1-6 alkyl;or

R7, and R8 can be taken together to form a monocyclic or a bicyclic saturated or partially unsaturated carbocyclyl or heterocyclyl ring optionally having 1-5 heteroatoms selected from O, N, or S, wherein the monocyclic or a bicyclic ring carbocyclyl or heterocyclyl is further optionally substituted with 1 to 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, nitro, cyano, -(CRaRb)mOR6, -SR6, -(CRaRb)mNR7R8, oxo, C1-6 alkylsulfonyl, -(CRaRb)mCOOR6, -(CRaRb)mC(O)NR7R8, C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, or C5-10 heteroaryl,wherein C3-6 cycloalkyl, C6-10 aryl, C5-10 heterocyclyl, and C5-10 heteroaryl are optionally substituted with C1-6 alkyl; Ra, and Rb are independently selected from the group consisting of hydrogen, -OR6, halogen, C1-6 haloalkyl, perhalo C1-6 alkyl, -SOpR1, and C1-6 alkyl; or Ra, and Rb can be taken together to form a monocyclic or a bicyclic ring saturated or partially unsaturated optionally having 1-5 heteroatoms selected from O, N or S; and m is 0 to 4; and X and Y is independently selected from halogen, CF₃ SO₃ -, boronate ester or boronic acid, provided X and Y cannot be the same. 13. A pharmaceutical composition comprising a compound of Formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, or a pharmaceutically acceptable salt thereof as claimed in any of claims 1 to 9 together with a pharmaceutically acceptable carrier, optionally in combination with one or more other pharmaceutical compositions. 14. The pharmaceutical composition as claimed in claim 13, wherein the composition is in the form of a tablet, capsule, powder, syrup, solution, aerosol, or suspension. 15. The compound as claimed in any of the claims 1 – 9, for use in the manufacture of a medicament of disease states mediated by GPR91. 16. A method for the treatment and/or prevention of various diseases, including cancer and infectious diseases, comprising administering to a subject suffering from the proliferative disorder or cancer, a therapeutically effective amount of the compound as claimed in any one of claims 1 – 9, or the pharmaceutical composition as claimed in claim 13, or 14, with other clinically relevant cytotoxic agents or non-cytotoxic agents to a subject in need thereof. 17. Use of the compounds as claimed in any one of claims 1 – 9, or the pharmaceutical composition as claimed in claim 13 or 14, for the treatment and/or prevention of various diseases including proliferative disorder or cancer; or treatment of cancer together with other clinically relevant cytotoxic agents or non-cytotoxic agents. 18. A method for the treatment of neovascularization, macular degeneration, diabetic nephropathy, liver diseases, inflammation, cancer, metabolic diseases, cardiovascular disease, hypertension, non alcoholic steatohepetitis (NAASH), fatty liver disease (FLD), non

alcoholic fatty liver disease (NAFLD), retinal angiogenesis , said method comprising administering a combination of the compounds as claimed in any of claims 1 – 9, or the pharmaceutical composition as claimed in claim 13 or 14, with other clinically relevant cytotoxic agents or non-cytotoxic agents to a subject in need thereof. 19. A method of treatment of as claimed in claim 18, said method comprising administering a combination of the compounds as claimed in any of claims 1 – 9, or the pharmaceutical composition as claimed in claim 13 or 14, with other clinically relevant immune modulators agents to a subject in need of thereof.

Documents

Sign in to open
Orders
Section
Application documents
1 Form3_As Filed_13-03-2017.pdf 13 Mar 2017
2 Form2 Title Page_Provisional_13-03-2017.pdf 13 Mar 2017
3 Form1_As Filed_13-03-2017.pdf 13 Mar 2017
4 Description Provisional_As Filed_13-03-2017.pdf 13 Mar 2017
5 Correspondence by Applicant_Provisional Filing_13-03-2017.pdf 13 Mar 2017
6 Abstract_As Filed_13-03-2017.pdf 13 Mar 2017
7 201741008624-RELEVANT DOCUMENTS [03-01-2018(online)].pdf 03 Jan 2018
8 201741008624-PA [03-01-2018(online)].pdf 03 Jan 2018
9 201741008624-Changing Name-Nationality-Address For Service [03-01-2018(online)].pdf 03 Jan 2018
10 201741008624-ASSIGNMENT DOCUMENTS [03-01-2018(online)].pdf 03 Jan 2018
11 201741008624-8(i)-Substitution-Change Of Applicant - Form 6 [03-01-2018(online)].pdf 03 Jan 2018
12 Correspondence by Agent_Assignment_08-01-2018.pdf 08 Jan 2018
13 201741008624-CORRESPONDENCE-OTHERS [13-03-2018(online)].pdf 13 Mar 2018
14 201741008624-COMPLETE SPECIFICATION [13-03-2018(online)].pdf 13 Mar 2018
15 201741008624-Annexure [13-03-2018(online)].pdf 13 Mar 2018
16 201741008624-CERTIFIED COPIES TRANSMISSION TO IB [21-03-2018(online)].pdf 21 Mar 2018
17 201741008624-RELEVANT DOCUMENTS [05-06-2018(online)].pdf 05 Jun 2018
18 201741008624-Proof of Right (MANDATORY) [05-06-2018(online)].pdf 05 Jun 2018
19 201741008624-PETITION UNDER RULE 137 [05-06-2018(online)].pdf 05 Jun 2018
20 Correspondence by Agent _Form 1_07-06-2018.pdf 07 Jun 2018
21 201741008624-FORM 3 [24-08-2018(online)].pdf 24 Aug 2018
22 201741008624-FORM 3 [14-02-2020(online)].pdf 14 Feb 2020
23 201741008624-FORM 18 [23-02-2021(online)].pdf 23 Feb 2021
24 201741008624-Information under section 8(2) [15-09-2021(online)].pdf 15 Sep 2021
25 201741008624-FER_SER_REPLY [17-09-2021(online)].pdf 17 Sep 2021
26 201741008624-CLAIMS [17-09-2021(online)].pdf 17 Sep 2021
27 201741008624-FER.pdf 17 Oct 2021
28 201741008624-US(14)-HearingNotice-(HearingDate-07-04-2022).pdf 15 Mar 2022
29 201741008624-REQUEST FOR ADJOURNMENT OF HEARING UNDER RULE 129A [04-04-2022(online)].pdf 04 Apr 2022
30 201741008624-US(14)-ExtendedHearingNotice-(HearingDate-11-05-2022).pdf 06 Apr 2022
31 201741008624-Correspondence to notify the Controller [02-05-2022(online)].pdf 02 May 2022
32 201741008624-FORM-26 [10-05-2022(online)].pdf 10 May 2022
33 201741008624-Written submissions and relevant documents [26-05-2022(online)].pdf 26 May 2022
34 201741008624-PatentCertificate31-05-2022.pdf 31 May 2022
35 201741008624-IntimationOfGrant31-05-2022.pdf 31 May 2022
36 201741008624-FORM-27 [29-09-2026(online)].pdf 29 Sep 2026
37 201741008624-FORM-27 [29-09-2026(online)]-2.pdf 29 Sep 2026
38 201741008624-FORM-27 [29-09-2026(online)]-1.pdf 29 Sep 2026
Search strategy
1searchE_22-03-2021.pdf

ERegister / renewals

Inforce
3rd Renewed 16 Aug 2022 Period 13 Mar 2019 – 13 Mar 2020 · CBR 32479 · Certificate 54003 ₹4,000
4th Renewed 16 Aug 2022 Period 13 Mar 2020 – 13 Mar 2021 · CBR 32479 · Certificate 54004 ₹4,000
5th Renewed 16 Aug 2022 Period 13 Mar 2021 – 13 Mar 2022 · CBR 32479 · Certificate 54005 ₹4,000
6th Renewed 16 Aug 2022 Period 13 Mar 2022 – 13 Mar 2023 · CBR 32479 · Certificate 54006 ₹4,000
7th Renewed 14 Feb 2023 Period 13 Mar 2023 – 13 Mar 2024 · CBR 6760 · Certificate 11694 ₹12,000
8th Renewed 06 Mar 2024 Period 13 Mar 2024 – 13 Mar 2025 · CBR 14695 · Certificate 43912 ₹12,000
9th Renewed 06 Mar 2025 Period 13 Mar 2025 – 13 Mar 2026 · CBR 13314 · Certificate 17564 ₹12,000
10th Renewed 11 Mar 2026 Period 13 Mar 2026 – 13 Mar 2027 · CBR 19580 · Certificate 20350 ₹12,000